BIOMARIN PHARMACEUTICAL INC Payments to Acquire Debt Securities, Available-for-sale
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Payments to Acquire Debt Securities, Available-for-sale of $147.36 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-04-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2022-04-29
- BIOMARIN PHARMACEUTICAL INC payments to acquire debt securities, available-for-sale for the quarter ending 2022-03-31 was $147.36M, a 37.87% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC payments to acquire debt securities, available-for-sale for the quarter ending 2021-12-31 was $200.00M, a 25.22% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC payments to acquire debt securities, available-for-sale for the quarter ending 2021-09-30 was $252.57M, a 423.38% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC payments to acquire debt securities, available-for-sale for the quarter ending 2021-06-30 was $247.40M, a 12.14% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC payments to acquire debt securities, available-for-sale for fiscal 2021 was $937.14M, a 76.93% increase from fiscal 2020.
- BIOMARIN PHARMACEUTICAL INC payments to acquire debt securities, available-for-sale for fiscal 2020 was $529.66M, a 16.20% decline from fiscal 2019.
- BIOMARIN PHARMACEUTICAL INC payments to acquire debt securities, available-for-sale for fiscal 2019 was $632.02M, a 0.43% decline from fiscal 2018.
- BIOMARIN PHARMACEUTICAL INC payments to acquire debt securities, available-for-sale for fiscal 2018 was $634.75M, a 3.16% decline from fiscal 2017.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2022-03-31 | $147.36M 10-Q · filed 2022-04-29 | $347.36M derived: sum of 2 quarters · filed 2022-04-29 | $599.93M derived: sum of 3 quarters · filed 2022-04-29 | $847.33M derived: sum of 4 quarters · filed 2022-04-29 |
| 2021-12-31 | $200.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $452.57M derived: sum of 2 quarters · filed 2022-02-25 | $699.97M derived: sum of 3 quarters · filed 2022-02-25 | $937.14M 10-K · filed 2022-02-25 |
| 2021-09-30 | $252.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $499.97M derived: sum of 2 quarters · filed 2021-10-29 | $737.14M 10-Q · filed 2021-10-29 | $896.87M derived: sum of 4 quarters · filed 2022-04-29 |
| 2021-06-30 | $247.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $484.57M 10-Q · filed 2021-07-30 | $644.29M derived: sum of 3 quarters · filed 2022-04-29 | $692.55M derived: sum of 4 quarters · filed 2022-04-29 |
| 2021-03-31 | $237.17M 10-Q · filed 2022-04-29 | $396.89M derived: sum of 2 quarters · filed 2022-04-29 | $445.15M derived: sum of 3 quarters · filed 2022-04-29 | $726.73M derived: sum of 4 quarters · filed 2022-04-29 |
| 2020-12-31 | $159.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $207.98M derived: sum of 2 quarters · filed 2022-02-25 | $489.56M derived: sum of 3 quarters · filed 2022-02-25 | $529.66M 10-K · filed 2022-02-25 |
| 2020-09-30 | $48.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $329.84M derived: sum of 2 quarters · filed 2021-10-29 | $369.94M 10-Q · filed 2021-10-29 | $473.47M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $281.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $321.68M 10-Q · filed 2021-07-30 | $425.21M derived: sum of 3 quarters · filed 2022-02-25 | $567.39M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $40.10M 10-Q · filed 2021-04-30 | $143.63M derived: sum of 2 quarters · filed 2022-02-25 | $285.81M derived: sum of 3 quarters · filed 2022-02-25 | $432.28M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $103.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $245.70M derived: sum of 2 quarters · filed 2022-02-25 | $392.18M derived: sum of 3 quarters · filed 2022-02-25 | $632.02M 10-K · filed 2022-02-25 |
| 2019-09-30 | $142.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $288.65M derived: sum of 2 quarters · filed 2020-11-06 | $528.50M 10-Q · filed 2020-11-06 | $724.05M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $146.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $386.32M 10-Q · filed 2020-08-05 | $581.88M derived: sum of 3 quarters · filed 2021-02-26 | $675.62M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $239.84M 10-Q · filed 2020-05-01 | $435.40M derived: sum of 2 quarters · filed 2021-02-26 | $529.14M derived: sum of 3 quarters · filed 2021-02-26 | $728.66M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $195.56M derived: 10-K 12 month − 10-Q/A 9 month · filed 2021-02-26 | $289.30M derived: sum of 2 quarters · filed 2021-02-26 | $488.82M derived: sum of 3 quarters · filed 2021-02-26 | $634.75M 10-K · filed 2021-02-26 |
| 2018-09-30 | $93.74M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2019-11-04 | $293.26M derived: sum of 2 quarters · filed 2019-11-04 | $439.20M 10-Q/A · filed 2019-11-04 | $484.85M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $199.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $345.46M 10-Q · filed 2019-08-02 | $391.11M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2018-03-31 | $145.93M 10-Q · filed 2019-04-29 | $191.59M derived: sum of 2 quarters · filed 2020-02-27 | ||
| 2017-12-31 | $45.65M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $655.45M 10-K · filed 2020-02-27 | ||
| 2017-09-30 | $609.79M 10-Q · filed 2018-10-26 | |||
| 2016-12-31 | $699.75M 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $873.18M 10-K · filed 2018-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |